AU2017302330A1 - Combination therapies for treating cancer - Google Patents
Combination therapies for treating cancer Download PDFInfo
- Publication number
- AU2017302330A1 AU2017302330A1 AU2017302330A AU2017302330A AU2017302330A1 AU 2017302330 A1 AU2017302330 A1 AU 2017302330A1 AU 2017302330 A AU2017302330 A AU 2017302330A AU 2017302330 A AU2017302330 A AU 2017302330A AU 2017302330 A1 AU2017302330 A1 AU 2017302330A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- formula
- chemotherapeutic agent
- doxorubicin
- leukemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- VYCADPDVDFTZFI-UHFFFAOYSA-N Brc1ccc(C2OCCO2)nc1 Chemical compound Brc1ccc(C2OCCO2)nc1 VYCADPDVDFTZFI-UHFFFAOYSA-N 0.000 description 1
- 0 FC(Oc(cc1)cc2c1[n]c(-c(cc1)ncc1OCC*CCOc1ccc(-c3nc4cc(OC(F)(F)F)ccc4[n]3)nc1)n2)(F)F Chemical compound FC(Oc(cc1)cc2c1[n]c(-c(cc1)ncc1OCC*CCOc1ccc(-c3nc4cc(OC(F)(F)F)ccc4[n]3)nc1)n2)(F)F 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662367263P | 2016-07-27 | 2016-07-27 | |
| US62/367,263 | 2016-07-27 | ||
| PCT/US2017/044124 WO2018022855A1 (en) | 2016-07-27 | 2017-07-27 | Combination therapies for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2017302330A1 true AU2017302330A1 (en) | 2019-01-17 |
Family
ID=61016782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017302330A Abandoned AU2017302330A1 (en) | 2016-07-27 | 2017-07-27 | Combination therapies for treating cancer |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11241421B2 (enExample) |
| EP (1) | EP3490557B1 (enExample) |
| JP (1) | JP2019525924A (enExample) |
| KR (1) | KR20190032370A (enExample) |
| CN (1) | CN109475542A (enExample) |
| AU (1) | AU2017302330A1 (enExample) |
| BR (1) | BR112019000049A2 (enExample) |
| CA (1) | CA3028461A1 (enExample) |
| EA (1) | EA201990395A1 (enExample) |
| IL (1) | IL263942A (enExample) |
| MX (1) | MX2019000179A (enExample) |
| WO (1) | WO2018022855A1 (enExample) |
| ZA (1) | ZA201900438B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019226975A1 (en) | 2018-05-24 | 2019-11-28 | University Of Virginia Patent Foundation | Combination therapies for treating cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5643935A (en) | 1995-06-07 | 1997-07-01 | The University Of North Carolina At Chapel Hill | Method of combatting infectious diseases using dicationic bis-benzimidazoles |
| US6372719B1 (en) * | 1998-03-04 | 2002-04-16 | Jay Cunningham | ανβ3 integrin antagonists in combination with chemotherapeutic agents |
| US8106033B2 (en) * | 2005-03-11 | 2012-01-31 | Temple University - Of The Commonwealth System Of Higher Education | Composition and methods for the treatment of proliferative diseases |
| AU2006269492A1 (en) * | 2005-07-06 | 2007-01-18 | Kanisa Pharmaceuticals, Inc. | Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer |
| EP2430016B1 (en) * | 2009-05-13 | 2020-04-01 | University Of Virginia Patent Foundation | Inhibitors of inv(16) leukemia |
-
2017
- 2017-07-27 US US16/318,041 patent/US11241421B2/en active Active
- 2017-07-27 EP EP17835254.8A patent/EP3490557B1/en active Active
- 2017-07-27 KR KR1020197001728A patent/KR20190032370A/ko not_active Ceased
- 2017-07-27 CN CN201780045352.0A patent/CN109475542A/zh active Pending
- 2017-07-27 MX MX2019000179A patent/MX2019000179A/es unknown
- 2017-07-27 EA EA201990395A patent/EA201990395A1/ru unknown
- 2017-07-27 JP JP2019503517A patent/JP2019525924A/ja active Pending
- 2017-07-27 AU AU2017302330A patent/AU2017302330A1/en not_active Abandoned
- 2017-07-27 CA CA3028461A patent/CA3028461A1/en not_active Abandoned
- 2017-07-27 BR BR112019000049-6A patent/BR112019000049A2/pt not_active IP Right Cessation
- 2017-07-27 WO PCT/US2017/044124 patent/WO2018022855A1/en not_active Ceased
-
2018
- 2018-12-24 IL IL263942A patent/IL263942A/en unknown
-
2019
- 2019-01-22 ZA ZA201900438A patent/ZA201900438B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3490557B1 (en) | 2022-09-07 |
| IL263942A (en) | 2019-02-28 |
| US20190343820A1 (en) | 2019-11-14 |
| EP3490557A1 (en) | 2019-06-05 |
| KR20190032370A (ko) | 2019-03-27 |
| CN109475542A (zh) | 2019-03-15 |
| WO2018022855A1 (en) | 2018-02-01 |
| MX2019000179A (es) | 2019-06-20 |
| EP3490557A4 (en) | 2020-04-01 |
| US11241421B2 (en) | 2022-02-08 |
| BR112019000049A2 (pt) | 2019-04-02 |
| ZA201900438B (en) | 2019-10-30 |
| EA201990395A1 (ru) | 2019-07-31 |
| CA3028461A1 (en) | 2018-02-01 |
| JP2019525924A (ja) | 2019-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2811367T3 (es) | Análogos de éteres fosfolipídicos como vehículos de fármacos que seleccionan como objetivo el cáncer | |
| US11446309B2 (en) | Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors | |
| CN105873440B (zh) | 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途 | |
| JP2024166290A (ja) | 血液癌の併用療法 | |
| CN101273989A (zh) | 一类小檗胺衍生物及其盐的应用 | |
| KR20200123137A (ko) | 삼치환 벤조트리아졸 유도체의 사용 방법 | |
| WO2016014778A1 (en) | Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes | |
| TW201006823A (en) | Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis | |
| KR102336767B1 (ko) | 골수증식성 신생물 및 만성 골수성 백혈병을 포함하는, 트랜스듀신 β―유사 단백질 １（ＴＢＬ １） 활성과 관련된 질환 또는 장애의 치료 방법 | |
| KR101930859B1 (ko) | 피라지노-트리아진 유도체를 포함하는 비소세포성폐암 예방 및 치료용 조성물 | |
| EP3490557B1 (en) | Combination therapies for treating cancer | |
| TWI753178B (zh) | Mcl-1抑制劑與血液癌症標準療法之組合，其用途及醫藥組合物 | |
| WO2014047782A1 (zh) | 含有白藜芦醇及白藜芦醇类衍生物和Bcl-2抑制剂的药物组合物及其应用 | |
| CA2398643A1 (en) | Novel compounds | |
| HK40003583A (en) | Combination therapies for treating cancer | |
| WO2020242910A1 (en) | Compositions and methods for treating cancer | |
| CN102083436A (zh) | 抗肿瘤组合物和方法 | |
| WO2022216930A1 (en) | Novel mda-9 antagonist with anti-metastatic potential | |
| WO2025174879A1 (en) | Methods of reducing or eliminating measurable residual disease | |
| KR20230142733A (ko) | 암 치료용 조성물 및 방법 | |
| HK40042533A (en) | Phospholipid ether analogs as cancer-targeting drug vehicles | |
| GB2504550A (en) | Diarylurea compound PQ401 for inhibiting the growth and/or proliferation of cancer stem cells | |
| HK40025641A (en) | Combination of a mcl-1 inhibitor and a standard of care treatment for hematologic cancers, uses and pharmaceutical compositions thereof | |
| HK1229695A1 (en) | Novel methods for treating cancer | |
| WO2011152515A1 (ja) | インドール化合物を含有する抗腫瘍剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |